Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

被引：6
|
作者：
Usmani, Saad Z. [1 ]
Nahi, Hareth [2 ]
Mateos, Maria-Victoria [3 ]
Lokhorst, Henk M. [4 ]
Chari, Ajai [5 ]
Kaufman, Jonathan L. [6 ]
Moreau, Philippe [7 ]
Oriol, Albert [8 ]
Plesner, Torben [9 ,10 ,11 ]
Benboubker, Lotfi [12 ]
Hellemans, Peter [13 ]
Masterson, Tara [14 ]
Clemens, Pamela L. [15 ]
Ahmadi, Tahamtan [15 ]
Liu, Kevin [16 ]
San-Miguel, Jesus [17 ]
机构：
[1] Levine Canc Inst Carolinas HealthCare Syst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA
[2] Karolinska Univ Hosp, Karolinska Inst, Div Hematol, Huddinge, Sweden
[3] Univ Hosp Salamanca IBSAL, Salamanca, Spain
[4] Vrije Univ Amsterdam Med Ctr, Dept Hematol, Amsterdam, Netherlands
[5] Tisch Canc Inst, Mt Sinai Sch Med, New York, NY USA
[6] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[7] Nantes Univ Hosp, Dept Hematol, Nantes, France
[8] HGTiP, Inst Catala Oncol, Barcelona, Spain
[9] Univ So Denmark, Vejle Hosp, Ctr Little Belt, Dept Hematol, Vejle, Denmark
[10] Vejle Hosp, Dept Hematol, Vejle, Denmark
[11] Univ So Denmark, Vejle, Denmark
[12] CHU Tours Hop Bretonneau, Tours, France
[13] Janssen Res & Dev, Beerse, Belgium
[14] Janssen Res & Dev, Spring House, PA USA
[15] Janssen Res & Dev, LLC, Spring House, PA USA
[16] Janssen Res & Dev, LLC, Raritan, NJ USA
[17] Clin Univ Navarra CIMA, IDISNA, Pamplona, Spain
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.1149.1149
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1149
引用
收藏
页数：6
相关论文
共 50 条
  • [21] A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
    Zonder, Jeffrey A.
    Mohrbacher, Ann F.
    Singhal, Seema
    van Rhee, Frits
    Bensinger, William I.
    Ding, Han
    Fry, John
    Afar, Daniel E. H.
    Singhal, Anil K.
    BLOOD, 2012, 120 (03) : 552 - 559
  • [22] An Open-label Dose-escalation Study of BIBF 1120 in Patients with Relapsed or Refractory Multiple Myeloma
    Kropff, Martin
    Kienast, Joachim
    Bisping, Guido
    Berdel, Wolfgang E.
    Gaschler-Markefski, Birgit
    Stopfer, Peter
    Stefanic, Martin
    Munzert, Gerd
    ANTICANCER RESEARCH, 2009, 29 (10) : 4233 - 4238
  • [23] Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study
    Shinsuke Iida
    Kenshi Suzuki
    Shigeru Kusumoto
    Masaki Ri
    Nobuhiro Tsukada
    Yu Abe
    Masayuki Aoki
    Mitsuo Inagaki
    International Journal of Hematology, 2017, 106 : 541 - 551
  • [24] Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study
    Iida, Shinsuke
    Suzuki, Kenshi
    Kusumoto, Shigeru
    Ri, Masaki
    Tsukada, Nobuhiro
    Abe, Yu
    Aoki, Masayuki
    Inagaki, Mitsuo
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 106 (04) : 541 - 551
  • [25] A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
    Stakiw, Julie
    Kodad, Shruthi
    LeBlanc, Richard
    Sebag, Michael
    Hay, Annette E.
    Kukreti, Vishal
    Cote, Julie
    Camacho, Fernando
    Fu, Molei
    Gul, Engin
    Reece, Donna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (07): : 484 - 490
  • [26] Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Hari, Parameswaran
    Paba-Prada, Claudia E.
    Voorhees, Peter M.
    Frye, John
    Chang, Yu-Lin
    Moreau, Philippe
    Zonder, Jeffrey
    Boccia, Ralph
    Shain, Kenneth H.
    LEUKEMIA RESEARCH, 2019, 83
  • [27] A Phase 1b, Open-Label Study of Eftozanermin Alfa in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Richardson, Paul G.
    Polepally, Akshanth R.
    Motwani, Monica
    Mu, Yunming
    Salman, Zeena
    Penugonda, Sudhir
    Moreau, Philippe
    BLOOD, 2020, 136
  • [28] AN OPEN-LABEL, MULTICENTER, PHASE 1B STUDY OF DARATUMUMAB IN COMBINATION WITH POMALIDOMIDE-DEXAMETHASONE AND WITH BACKBONE REGIMENS IN PATIENTS WITH MULTIPLE MYELOMA
    Mateos, M. V.
    Moreau, P.
    Comenzo, R.
    Blade, J.
    Benboubker, L.
    de la Rubia, J.
    Facon, T.
    Fay, J.
    Qin, X.
    Masterson, T.
    Schecter, J.
    Ahmadi, T.
    San-Miguel, J.
    HAEMATOLOGICA, 2015, 100 : 84 - 84
  • [29] Subcutaneous Daratumumab Plus Carfilzomib and Dexamethasone (D-Kd) in Relapsed/Refractory Multiple Myeloma: An Open-label, Multicenter, Phase 2 Study (PLEIADES)
    Chari, Ajai
    Goldschmidt, Hartmut
    Yang, Shiyi
    Kosh, Michele
    Delioukina, Maria
    Qi, Ming
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E144 - E144
  • [30] Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    Stiff, Patrick J.
    Maharaj, Michele
    Oliver, Katherine
    Callander, Natalie Scott
    BLOOD, 2016, 128 (22)
12345